MK-3697 is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), primarily utilized in pharmaceutical research and development for the treatment of type 2 diabetes and related metabolic disorders such as obesity. By inhibiting SGLT2 in the kidneys, it reduces glucose reabsorption, promotes urinary glucose excretion, and lowers blood glucose levels. It is investigated for its potential to improve insulin sensitivity, regulate glucose and lipid metabolism, reduce body weight, lower blood pressure, and mitigate cardiovascular risk factors including dyslipidemia. Researchers explore its efficacy in preclinical and clinical trials, evaluating safety, pharmacokinetics, and pharmacodynamics to assess its suitability as a novel therapeutic agent.